Flavin‐Containing Monooxygenase 3 Polymorphic Variants Significantly Affect Clearance of Tamoxifen and Clomiphene. Issue 6 (2nd August 2018)

• Record Type: Journal Article
• Authors: Catucci, Gianluca; Bortolussi, Stefania; Rampolla, Giulia; Cusumano, Debora; Gilardi, Gianfranco; Sadeghi, Sheila J.
• Is Part Of: Basic & clinical pharmacology & toxicology. Volume 123:Issue 6(2018)
• Page Start: 687
• Page End: 691
• Publication Date: 2018-08-02
• Subjects: Pharmacology -- Periodicals; Toxicology -- Periodicals; Pharmacology -- Periodicals; Toxicology -- Periodicals; Pharmacology, Clinical -- Periodicals; Computer network resources; Electronic journals; 615.1
• DOI: 10.1111/bcpt.13089
• Languages: English
• ISSNs: 1742-7835

Abstract

Abstract: Human flavin‐containing monooxygenase 3 (hFMO3) is a drug‐metabolising enzyme that oxygenates many drugs and xenobiotics in the liver. This enzyme is also known to exhibit single nucleotide polymorphisms (SNPs) that can alter the rates of monooxygenation of therapeutic agents. The purpose of this study was to investigate the effect of the three common polymorphic variants of hFMO3 (V257M, E158K and E308G) on the metabolism and clearance of three structurally similar compounds: tamoxifen (breast cancer medication), clomiphene (infertility medication) and GSK5182 (antidiabetic lead molecule). For GSK5182, none of the three variants showed any significant differences in its metabolism when compared to the wild‐type enzyme. In the case of clomiphene, two of the variants, V257M and E308G, exhibited a significant increase in all the kinetic parameters measured with nearly two times faster clearance. Finally, for tamoxifen, a mixed behaviour was observed; E158K variant showed a significantly higher clearance compared to the wild type, whereas V257M mutation had the opposite effect. Overall, the data obtained demonstrate that there is no direct correlation between the SNPs and the metabolism of these three hFMO3 substrates. The metabolic capacity is both variant‐dependent and substrate‐dependent and therefore when testing new drugs or administering already approved therapies, these differences should be taken into consideration.